Connect with us

Hi, what are you looking for?

Right Decision NowRight Decision Now


These Stocks Have Been The Stars Of 3rd Quarter Earnings Season – And Many Are Poised To Trade Much Higher

Most stocks in the S&P 500 have reported 3rd quarter results and while a lower than average number reported above estimates, many that had positive results have gone on to trade higher in moves that still have further upside during the current bear market rally.

The biggest winners among these companies reporting positive earnings were stocks that immediately posted a gap up in price on high volume; which then led to a base breakout. This is one of the most powerful chart patterns and often will lead to further gains that are much higher than the markets.


To begin, the higher than average volume during the gap up in price indicates strong demand for the stock that in most cases will take more than one day to fulfill. One reason for the strong demand is the strong earnings which has been proven to be the primary driver of stocks that go on to far outpace the markets.

Over the days following the better than expected earnings report, Wall Street analysts will often begin to raise their price target for the stock – which was the case for Air Products & Chemical (APD) – and this will provide a secondary boost. The latest price target upgrade for APD is $390 which is 18% above the current price. 

Of course, these stocks won’t go on to trade higher forever. Your first signal that the uptrend is over will be a move of the RSI into negative territory (below 50) on the daily chart. Price action within the broader markets will impact these leading stocks as well.


Above is a chart for Five Below (FIVE) which gapped up into a base breakout last Thursday after reporting earnings that were 93% above estimates. In addition, management raised their guidance going into year-end due to robust holiday sales. In turn, Wall Street raised their price target to  $200 which is about 10% above its current price.

Five Below’s supersized rally pushed the stock out of a 5-month base which is constructive, as the longer your base breakout the longer your possible advance out of that base.

Strong earnings are not the only reason that stocks gap up into base breakouts as one of the Biotechnology stocks from my MEM Edge Report has just entered an uptrend out of a base due to positive clinical trial news for one of their drugs. In addition, the company is estimated to grow earnings by 207% next year. To receive immediate access to this stock that is just beginning to trend higher, use this link here for a 4-week trial at a nominal fee. You’ll also have access to my other top picks.

In addition, my bi-weekly MEM Edge Report provides insights into what to expect for the markets going into year end as well as which areas of the market you should overweighting. Take advantage of this offer now!


Mary Ellen McGonagle, MEM Investment Research

    You May Also Like


    The head of the International Monetary Fund has warned of increased risks to the stability of the financial system after weeks of banking sector...


    The Home Office has made next to no progress in tackling criminal fraud during the past five years, despite it having become Britain’s most...


    Mark Zuckerberg has laid off more than 11,000 Meta’s employees, about 13 per cent of its global workforce, in what he described as “some...


    1.22 billion people use Instagram every month. That’s a huge number of Instagrammers trying to hit it big on the platform all at the...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 | All Rights Reserved